Predominant Dissemination of PVL-Negative CC89 MRSA with SCCmec Type II in Children with Impetigo in Japan
Table 4
Comparison of antimicrobial susceptibilities of MRSA and MSSA.
Antimicrobial agent
Resistance breakpoint (g/mL)
MSSA ()
MRSA ()
Range (μg/mL)
MIC90 (μg/mL)
Resistance (%)
Range (μg/mL)
MIC90 (μg/mL)
Resistance (%)
MPIPC
4
≦2
≦2
0
4–>8
>8
100
ABPC
0.5
≦0.125–>16
16
71.3
4–>16
>16
100
CCL
16
1–16
4
1.6
4–>16
>16
92.9
CDTR
2*
0.5 –2
1
0.8
2–>16
>16
100
CAM
4
≦0.125–>16
>16
67.2
>16
>16
100
CLDM
1
≦0.125–0.25
0.25
0
≦0.125–>16
>16
71.4
FOM
8**
0.25–>16
16
20.5
1–>16
8
14.3
MINO
8
≦0.125–0.25
≦0.125
0
≦0.125–16
0.25
7.1
GM
8
0.25–>16
>16
54.1
1–>16
>16
92.9
VCM
4
≦0.5–1
1
0
1-2
1
0
NDFX
4**
≦0.125–2
≦0.125
0
≦0.125–>16
≦0.125
7.1
FA
2**
≦0.125–>16
0.5
0.82
≦0.125–1
0.5
0
The breakpoints for these antimicrobial agents were determined according to the interpretation criteria of Clinical and Laboratory Standards Institute (CLSI). Susceptibility to antimicrobial drugs for which breakpoints are not determined by CLSI was according to the interpretation criteria of the Japan Society for Chemotherapy (*) or defined in this study (**).
